Apolipoprotein B mRNA editing enzyme catalytic subunit 2 (APOBEC2)

Apolipoprotein B mRNA editing enzyme catalytic subunit 2 (**APOBEC2**) is a member of the cytidine deaminase enzyme family, which includes other apolipoprotein B mRNA editing enzymes[3]. In contrast to APOBEC1 and the APOBEC3 family, which are implicated in mRNA editing and cancer mutagenesis respectively, APOBEC2 does not demonstrate robust cytidine deaminase or RNA-editing activity in humans. Its physiological role is not fully established, but it is expressed primarily in cardiac and skeletal muscle and may play a part in muscle development and differentiation[3]. There is no strong evidence to support its direct involvement as a therapeutic target, receptor, or disease biomarker. Mutations or dysregulation of other APOBEC family members contribute to cancer and viral restriction, but APOBEC2 itself is not currently considered a clinically relevant molecular target[3]. **Additional context and clarification:** The name "apolipoprotein B mRNA editing enzyme catalytic subunit 2"—APOBEC2—distinguishes it from **APOBEC1**, which is the active enzyme responsible for cytidine-to-uridine RNA editing in apolipoprotein B mRNA and has defined biological and pathophysiological roles[5][1][3]. If you were seeking the clinically, pathophysiologically, or therapeutically significant **Apolipoprotein B mRNA editing enzyme**, the intended target may have been APOBEC1, not APOBEC2. Therefore, for "APOBEC2," is_incorrect: true, since it is not considered an established therapeutic target, has limited known function in humans, and does not play a role in mRNA editing or relevant disease processes[3]. If you need the structured information for APOBEC1—the canonical RNA-editing enzyme relevant to apolipoprotein B mRNA processing—please clarify.

Other names

Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 2APOBEC2Apobec-2